Home
Resources
Publications
Tiotropium Bromide in Children and Adolescents With Asthma

Tiotropium Bromide in Children and Adolescents With Asthma

Hengameh H Raissy, H William Kelly

Paediatr Drugs. 2017 Dec;19(6):533-538.

PMID: 28808948

Abstract:

Evidence is emerging on the use of long-acting muscarinic antagonists (LAMAs) in the management of asthma. Tiotropium bromide (Spiriva® Respimat®) is the only LAMA approved in children and adolescents. As the use of tiotropium becomes more common in clinical practice, it is necessary to review the existing data to identify patients who may benefit from the addition of this medication to their daily asthma regimen. This review discusses recent evidence on the safety and efficacy of tiotropium bromide in the management of asthma in children and adolescents. Current data support that tiotropium bromide has a bronchodilator effect, as evident by improvements in acute lung function compared with placebo; however, data are not yet available to present a stepwise approach or identify phenotypes that would benefit from the addition of tiotropium bromide. Well-designed studies are needed to compare the different step-up options to tiotropium bromide and provide an evidence-based stepwise approach for the management of asthma in children. Furthermore, study design should include identification of phenotypes that might experience a better clinical response to tiotropium bromide compared with other adjunct medications.

Chemicals Related in the Paper:

Catalog Number	Product Name	CAS Number	Price
AP1066371	Trimethylgermanium bromide	1066-37-1	Price
AP12265064	Ammonium-d4 bromide	12265-06-4	Price
AP29552587	i-Propylammonium bromide	29552-58-7	Price
LS72767	i-Butylammonium bromide		Price
LS7932269	4-Acetoxybutylzinc bromide		Price
LS7932278	Cyclobutylzinc bromide		Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: